Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Ghent
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with non-cystic adenocarcinoma the pancreas requiring neoadjuvant chemotherapy (any) because of borderline resectability
Patients with stage IIIC or IVA ovarian cancer planned for debulking and HIPEC.
Patients with stage IIIC or IVA colorectal cancer planned for debulking and HIPEC
You may not be if
Age \<18 years
Pregnancy, or suspected inadequate contraception during study period
Clinically detectable ascites
Intestinal or urinary tract obstruction
Hepatic and/or extra-abdominal metastatic disease
Impaired renal function (serum creatinine \> 1.5mg/dl or calculated GFR (CKD-EPI) \< 60mL/min/1.73 m²)
Impaired liver function (serum total bilirubin \> 1.5 mg/dl, except for known Gilbert's disease)
Platelet count \< 100.000/µl
Hemoglobin \< 9g/dl
Neutrophil granulocytes \< 1.500/ml
Irresectable or metastatic disease
Contra-indication for contrast enhanced MRI
* Known allergy or intolerance to Gadolinium based contrast agents
* Severe claustrophobia
* Patients with metallic foreign bodies (pacemaker, neurostimulator, pedicle screw, cerebral aneurysm clips…) that may dislodge in a strong magnetic field
Frail and medically unfit patients (Karnofsky index \< 60% and WHO Performance score 3 or 4)
Estimated life expectancy \< 12 months
In case of ovarian/colon cancer: no visible peritoneal metastasis on CT scan
Acute or chronic pancreatitis
Clareo Health | Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology
